Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

Bio2RDF uri

Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

http://bio2rdf.org/clinicaltrials:NCT01882179

Bio2RDF identifier

NCT01882179

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01882179

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01882179

acronym [clinicaltrials_vocabulary:acronym]

MINIMISE-STEMI

http://www.w3.org/2001/XMLSchema#string

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

150

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01882179 arm group 354f5b721036db8744d92a5b1a3cfac9 [clinicaltrials_resource:NCT01882179/arm-group/354f5b721036db8744d92a5b1a3cfac9]

NCT01882179 arm group 6f8ce038bc50a5372fcaf86e4b300bb6 [clinicaltrials_resource:NCT01882179/arm-group/6f8ce038bc50a5372fcaf86e4b300bb6]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:268ba6cb6b0dfa2372547af2b60714ee

brief summary [clinicaltrials_vocabulary:brief-summary]

Heart attacks, or myoca ...... atients after a heart attack.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:64f684ae54324667dff871e740149002]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:0944291b9e57251768032486ebfb7a89]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:29003f0b817e64cd8d62d6604c8f5182]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:83a4192f8869ad868454a83c604b8934]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:b34a041da101c84986bd436581659a6a]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:e32efdfff767bd0f5a7d3b8c9b2c509a]

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging 12 weeks after STEMI [clinicaltrials_resource:f4d784cd08e7d095fe7d9abad39fbd9c]

collaborator [clinicaltrials_vocabulary:collaborator]

University College, London [clinicaltrials_resource:b73dfdf242788f236ba8f8f401b19e15]

completion date [clinicaltrials_vocabulary:completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01882179 [clinicaltrials_resource:b4c1ce5c5292814cdb6f956208f0f5bb]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

placebo [clinicaltrials_resource:25b0b2bca0000507675c23f7e1b0238e]

Mineralocorticoid receptor antagonist potassium-canrenoate [clinicaltrials_resource:bd9a2675b7e904681d8fe1683f13773b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Canrenoic Acid [clinicaltrials_resource:3d184bdd47b927431279289b7b53f115]

Mineralocorticoids [clinicaltrials_resource:b7e7656d52afd9a1efba4919d9c42ec9]

Mineralocorticoid Receptor Antagonists [clinicaltrials_resource:c170a8e14d98f2fb72eac4abe0f3b497]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

MRI

http://www.w3.org/2001/XMLSchema#string

Reperfusion injury

http://www.w3.org/2001/XMLSchema#string

myocardial infarct size

http://www.w3.org/2001/XMLSchema#string

spironolactone

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University College, London [clinicaltrials_resource:b73dfdf242788f236ba8f8f401b19e15]

location [clinicaltrials_vocabulary:location]

Cardiothoracic Center - Basildon and Thurrock University Hospitals [clinicaltrials_resource:c16e9364287ab09c5dbc1fc7d979987a]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01882179

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

MINeralocorticoid Receptor Ant ...... Myocardial Infarction (STEMI)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

12/0533

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Derek J Hausenloy, PhD [clinicaltrials_resource:2b217bc99805d56a43d9072b6c67e308]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Derek J Hausenloy, PhD [clinicaltrials_resource:fbcec29c9668fc368dee761de0fbc388]

overall official [clinicaltrials_vocabulary:overall-official]

Derek J Hausenloy, PhD [clinicaltrials_resource:886935a93d34901b7518353f4481ca65]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United Kingdom: Medicines and Healthcare Products Regulatory Agency [clinicaltrials_resource:6923140e34ebaa8b78d582136d7271d8]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

10471456 [pubmed:10471456]

12668699 [pubmed:12668699]

20028693 [pubmed:20028693]

21073363 [pubmed:21073363]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

University College, London [clinicaltrials_resource:b73dfdf242788f236ba8f8f401b19e15]

start date [clinicaltrials_vocabulary:start-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01882179 study design [clinicaltrials_resource:56de0d4c6e9c9dc773adeeb9a7bdb463]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01882179

verification date [clinicaltrials_vocabulary:verification-date]

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01882179

http://www.w3.org/2001/XMLSchema#string

title

Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

@en